Make a donation
Research budgets seem huge. And people often wonder if their support makes a real difference. Of course it does!
Why support BIG?
Your donations represent hope - your donations represent LIFE!
By making a donation, you help the millions of patients around the world and thousands of researchers who – thanks to your support –work tirelessly to develop new treatments and therapies that improve the quality of life of women and men with breast cancer.
There are many areas of research that hold great promise for patients but have no particular interest for commercial partners. These studies hold tremendous potential for patients and promise long-term gains for society, in all regions of the world.
We need your help to make it happen.
For a minimum total donation of €40 per year, you are entitled to a tax certificate. You will automatically receive this certificate during the following year. The tax deduction amounts to 45% of the amount of your donation. For example: if you donate €40 to BIG against breast cancer, you will receive €18 back and only pay €22.
Academic trials that need your support
BIG Radio Tuning (EXPERT)
Aims to tailor the use of radiotherapy according to each patient’s risk of breast cancer relapse, ultimately hoping to identify those patients who can safely avoid this treatment. The results of this study could influence how 2 in 5 women with breast cancer are treated in the future.
BIG time for baby (POSITIVE)
Aims to evaluate whether it is safe for women to interrupt their endocrine therapy to try to conceive after breast cancer. This has been a terrible dilemma to young women wishing to have a child. If treatment is stopped to try to conceive, will it increase the risk of cancer recurrence? This is the kind of question the study intends to address.
Metastatic breast cancer GPS (AURORA)
Aims to improve our understanding of metastatic breast cancer, to identify genetic breakdowns, and to map the routes that cancer cells take to invade other organs. Its first phase recently completed and a second is being launched to focus on specific subtypes of the disease that are particularly aggressive.